



Pancreatic cancer trials open to recruitment – October 2026

This list includes trials targeted at pancreatic cancer alone and trials for many solid tumours which include pancreatic cancer. If you are a patient with pancreatic cancer and wish to discuss whether a clinical trial is right for you, please discuss with your treating Medical Oncologist.

NOTE: Trials listed are available for patients with pancreatic cancer to be referred for consideration. Several trials may have issues with slot availability or waitlists.

Descriptive stages of pancreatic cancer

Medical Term	What it means
Resectable	This is an early stage of pancreatic cancer where the cancer can still be removed by surgery.
Unresectable or locally advanced	The pancreatic cancer has not spread around the body but unfortunately the cancer cannot be removed by surgery due to the tumour size, location, or involvement of surrounding structures.
Metastatic	The pancreatic cancer has spread to other parts of the body.
<i>SOC</i>	<i>Standard of Care, which is the accepted, benchmark medical treatment routinely used for a specific type and stage of cancer.</i>



PANCREATIC CANCER TRIALS IN VICTORIA (Trials with specific cohorts for pancreatic cancer)					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
<u>NeoFOL-R</u> Efficacy of Neoadjuvant FOLFIRINOX in Resectable pancreatic cancer: An international multicentre Randomized, controlled trial (NeoFOL-R) - Australian protocol	N/A	RESECTABLE Exclusion: Borderline resectable Locally advanced Previous treatment for pancreatic cancer	mFOLFIRINOX chemotherapy Arm A: Surgery then 12 cycles of chemotherapy Arm B: 6 cycles of chemotherapy before surgery followed by 6 of cycles after surgery Further information: NeoFOL-R - Victorian Cancer Trials Link	Epworth Health	EJReissatiCentre@epworth.org.au
				Monash Health	gi.oncresearch@monashhealth.org
				Alfred Health	act-m@alfred.org.au
				St Vincent's Hospital	lynn.chong@svha.org.au
<u>River (C3651021)</u> A Study to Learn About the Medicine Ponesegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue	GDF-15	METASTATIC/LOCALLY ADVANCED (First line) Inclusion: Metastatic pancreatic ductal adenocarcinoma Can have received first cycle of chemotherapy but prior to second cycle Cachexia defined by Fearon criteria of weight loss	Ponesegromab is a monoclonal antibody aiming to treat cancer cachexia for targeting GDF-15 Patients are treated with first line chemotherapy (gemcitabine + nab-paclitaxel or mFOLFIRINOX) and randomized to receive ponesegromab or placebo Further information: https://clinicaltrials.gov/study/NCT06989437	Western Health	CancerClinicalTrials@wh.org.au



PANCREATIC CANCER TRIALS IN VICTORIA (Trials with specific cohorts for pancreatic cancer)					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
CA240-0030 / MountainTAP-30 A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion	MTAP deletion	METASTATIC/LOCALLY ADVANCED (First line) Inclusion: Untreated advanced pancreatic cancer Homozygous MTAP deletion	BMS-986504 Patients will receive gemcitabine and nab- paclitaxel combined with BMS-986504 (a novel PRMT5 inhibitor) or placebo. Further information: https://trials.cancervic.org.au/details/vctlnct07076121	Cabrini	clinicaltrials@cabrini.com.au
				Northern Hospital	cancerclinicaltrials@nh.org.au *Recruitment ON HOLD*
KANDLELIT-014 A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as Monotherapy and in Combination With Cetuximab, in Participants With KRAS G12C- Mutant, Advanced Solid Tumors (KANDLELIT-014)	KRAS G12C	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: Progression on standard of care therapy	MK-1084 is an oral KRAS G12C inhibitor. Patients will be treated alone or in combination with cetuximab. Further information: https://clinicaltrials.gov/study/NCT07209111	Epworth	EH-PancreaticCentre@epworth.org.au *RESTRICTED RECRUITMENT*



PANCREATIC CANCER TRIALS IN VICTORIA (Trials with specific cohorts for pancreatic cancer)					
Trial Title	Targets (Genomic)	Target population <i>(Trial suitable for patients with this stage of pancreatic cancer)</i>	Treatment + Further Information <i>(What the study involves)</i>	Site <i>(Where the study is being offered)</i>	Contact Details <i>(Email the contact person listed with any enquiries)</i>
<u>ADCE-T02 / AMT-754-01</u> First-in-Human, Phase 1 Study of ADCE-T02, a Targeting Tissue Factor Antibody-Drug Conjugate	N/A	ADVANCED UNRESECTABLE SOLID CANCERS	ADCE-T02 Phase 1 study testing safety and efficacy of ADCE-T02. This is an antibody-drug conjugate that targets the Tissue Factor protein that is often overexpressed on cancer cells Further information: https://trials.cancervic.org.au/details/vct1_nct06597721	Peninsula and South Eastern Haematology and Oncology Group	ag@paso.com.au
				Cabrini Health	clinicaltrials@cabrini.com.au *RESTRICTED RECRUITMENT* * NO SLOTS CURRENTLY AVAILABLE at CH*
<u>CS2009</u> A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS2009	N/A	ADVANCED, UNRESECTABLE SOLID CANCERS	CS2009 First in human study - Initial cohorts are testing safety and efficacy. CS2009 is a Tri-specific Antibody Targeting PD-1/VEGFA/CTLA-4 Further information: https://trials.cancervic.org.au/details/vct1_nct06741644	Monash Health	referrals.earlyphase@monashhealth.org
<u>BNT3214</u> Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumours	N/A	ADVANCED OR METASTATIC SOLID CANCERS	BNT3214 First in human study - Initial cohorts are testing safety and efficacy. BNT3214 is a bispecific antibody-drug conjugate that selectively delivers cytotoxic drugs directly to cancer cells Further information: https://clinicaltrials.gov/NCT0745573	Epworth	EH-PancreaticCentre@epworth.org.au
				Monash Health	referrals.earlyphase@monashhealth.org *RESTRICTED RECRUITMENT* *WAITLIST IN PLACE*



PANCREATIC CANCER TRIALS IN VICTORIA (Trials with specific cohorts for pancreatic cancer)					
Trial Title	Targets (Genomic)	Target population <i>(Trial suitable for patients with this stage of pancreatic cancer)</i>	Treatment + Further Information <i>(What the study involves)</i>	Site <i>(Where the study is being offered)</i>	Contact Details <i>(Email the contact person listed with any enquiries)</i>
			4		
<u>KONQUER-101</u> A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.	RAS	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: RAS mutant PDAC, CRC, NSCLC, or other solid tumour	BBO-11818 is a pan-RAS inhibitor and will be administered alone or in combinations with chemotherapy and/or pembrolizumab Further information: https://clinicaltrials.gov/study/NCT06917079	Peter MacCallum Cancer Centre	PCCTU.EDD@petermac.org
<u>FMT</u> Fecal Microbiota Transplantation to improve pain, symptom management and treatment efficacy in patients with pancreatic cancer	N/A	METASTATIC/LOCALLY ADVANCED <i>(First line)</i> Inclusion: Pancreatic cancer Exclusion: Antibiotic use within 8 weeks of randomisation (1 dose with ERCP allowed)	Fecal Microbiota Transplantation Further information: https://www.pancreaticcentre.org.au/treatment/clinical-trials-and-research/fmt	Epworth	EH-PancreaticCentre@epworth.org.au
<u>LuMIERE</u> A Phase 1/2, Multicentre, Open-label, Non-randomized Study to Investigate Safety and Tolerability,	FAP	METASTATIC/LOCALLY ADVANCED <i>(First line)</i> Inclusion:	[177Lu]Lu-FAP-2286 is a radiopharmaceutical that targets fibroblast activation protein (FAP). This treatment works by binding to the FAP to allow the	Peter MacCallum Cancer Centre	PCCTU.MoncC@petermac.org * RESTRICTED RECRUITMENT – PDAC 1L* * LIMITED SLOTS AVAILABLE*



PANCREATIC CANCER TRIALS IN VICTORIA (Trials with specific cohorts for pancreatic cancer)					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FAP-2286 in Patients With an Advanced Solid Tumour		Pancreatic ductal adenocarcinoma + other cancers <u>Combination cohort:</u> Chemotherapy naïve for advanced disease Exclusion: Active CNS disease	targeted delivery of radiation directly to FAP-expressing cancer cells. Further information: https://trials.cancervic.org.au/details/vct1_nct04939610	Alfred Health	act-m@alfred.org.au
<u>AP601</u> A Study of AP601 in Patients With Locally Unresectable Advanced or Metastatic Solid Tumors	CD73 + CD137	ADVANCED OR METASTATIC SOLID CANCERS (Second line +) Inclusion: Pancreatic ductal adenocarcinoma	<u>AP601</u> AP601 is a bispecific antibody that targets and inhibits CD73 on tumour cells and activates CD137 on T cells. AP601 is delivered as an infusion. Further information: https://www.pancreaticcentre.org.au/treatment/clinical-trials-and-research/ap601	Epworth	EH-PancreaticCentre@epworth.org.au
<u>AMG 410</u> A Phase 1/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors	KRAS	ADVANCED OR METASTATIC SOLID CANCERS (Exhausted standard of care) Inclusion: KRAS mutation or amplification Exhausted conventional treatment options Pancreatic cohort specified in part 2.	<u>AMG 410</u> AMG 410 is an oral pan-KRAS inhibitor and will be administered alone or in combination with pembrolizumab and panitumumab Further information: https://trials.cancervic.org.au/details/vct1_nct07094113	Peter MacCallum Cancer Centre	PCCTU.EDD@petermac.org



PANCREATIC CANCER TRIALS IN VICTORIA (Trials with specific cohorts for pancreatic cancer)					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
<u>EIK1004-101</u> A Phase 1/2, Open-label, Multicenter, Dose-escalation, and Dose-Optimization Study to Evaluate the Safety, Tolerability, and Activity of EIK1004 (IMP1707) as Monotherapy in Participants With Advanced Solid Tumors	HRR deficiency	METASTATIC/LOCALLY ADVANCED (Second line +) Inclusion: Suspected deleterious mutation of select HRR genes Exclusion: Prior PARP1 inhibitor	EIK1004 EIK1004 is an oral PARP1 inhibitor and will be administered as monotherapy Further information: https://trials.cancervic.org.au/details/vct1_nct06907043	Peninsula and South Eastern Haematology and Oncology Group	ag@paso.com.au
<u>EIK1005-002</u> A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors, Including Checkpoint Inhibitor Naive Participants With Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors	WRN (Werner helicase) + dMMR/ MSI-H	METASTATIC/LOCALLY ADVANCED (Second line +) Inclusion: Part 1a – all patients Part 1b and 2: Confirmed dMMR or MSI-H tumours	EIK1005 EIK1005 is a potent and selective inhibitor of WRN and is administered orally. Participants with receive ELK1005 as monotherapy or in combination with pembrolizumab Further information: https://trials.cancervic.org.au/details/vct1_nct07262619#	Grampians Health (Ballarat)	clinicaltrials@gh.org.au *RESTRICTED RECRUITMENT* *WAITLIST IN PLACE*
				Peninsula and South Eastern Haematology and Oncology Group	ag@paso.com.au *RESTRICTED RECRUITMENT*
<u>ALKOVE-1</u> A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-to655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-to1)	ALK	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: ALK rearrangement or activating ALK mutation	NVL655 NVL655 (neladalkib) is an oral selective ALK inhibitor. Further information: https://www.cancer.nsw.gov.au/cancer-clinical-trials-in-nsw/13595	Peter MacCallum Cancer Centre	PCCTU.MoncB@petermac.org



PANCREATIC CANCER TRIALS IN VICTORIA (Trials with specific cohorts for pancreatic cancer)					
Trial Title	Targets (Genomic)	Target population <i>(Trial suitable for patients with this stage of pancreatic cancer)</i>	Treatment + Further Information <i>(What the study involves)</i>	Site <i>(Where the study is being offered)</i>	Contact Details <i>(Email the contact person listed with any enquiries)</i>
<u>ARROS-1</u> A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)	ROS1	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: ROS1 rearrangement	Zidesamtinib (NVL-520) NVL-520 is an oral selective tyrosine kinase inhibitor. Further information: https://trials.cancervic.org.au/details.aspx?ID=feed-cta-trial477	Peter MacCallum Cancer Centre	PCCTU.MoncB@petermac.org
<u>DAWN-303 / INCB161734-303</u> A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)	KRAS G12D	METASTATIC (First line) Inclusion: Previously untreated for the metastatic disease.	Randomised Phase 3 study comparing SOC chemotherapy (mFOLFIRINOX or Gemcitabine plus nab-paclitaxel) with or without an experimental oral (INCB161734). Further information: https://clinicaltrials.gov/study/NC T07522073	Alfred	act-m@alfred.org.au
				Epworth	EH-PancreaticCentre@epworth.org.au
				PMCC UGI MoncC	PCCTU.MoncC@petermac.org
<u>RASolute 303 / RMC6236-303</u> RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel Versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients With Metastatic Pancreatic	KRAS & RAS variants	METASTATIC (First line) Inclusion: Previously untreated for the metastatic disease.	Randomised Phase 3 study comparing either SOC (gem/abraxane), oral Daraxonrasib alone or oral Daraxonrasib combine with SOC gem/abraxane. Further information: https://clinicaltrials.gov/study/NC T07491445	Austin	samantha.chakar@austin.org.au
				Epworth	EH-PancreaticCentre@epworth.org.au



PANCREATIC CANCER TRIALS IN VICTORIA (Trials with specific cohorts for pancreatic cancer)					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
Adenocarcinoma					
<u>M25-288</u> Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan in Combination With FOLFOX Compared to Standard of Care in Subjects With First-Line Metastatic Pancreatic Ductal Adenocarcinoma - AndroMETa-PDAC-288	c-MET	METASTATIC/LOCALLY ADVANCED (First line) Inclusion: Previously untreated (first-line therapy)	Investigation therapy is IV Telisotuzumab Adizutecan (an antibody-drug conjugate). Study has 2 phases: Phase 2 dose escalation/dose optimisation followed by Phase 3 randomised trial, comparing Telisotuzumab Adizutecan RP3D + FOLFOX and SOC mFOLFIRINOX Further information: https://clinicaltrials.gov/study/NCT07490301	Austin	samantha.chakar@austin.org.au
<u>IMM1104-301 / MapKeeper 301</u> A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination With the Modified Gemcitabine and Nab-Paclitaxel Regimen Versus the Standard Gemcitabine and Nab-Paclitaxel Regimen for the Treatment of Patients With Metastatic Pancreatic Ductal Pancreatic Adenocarcinoma Cancer (MAPKeeper 301)	MAPK pathway (including RAS & RAF driven cancers)	METASTATIC (First line) Inclusion: Previously untreated for the metastatic disease.	Randomized, Phase 3 study evaluating if treatment with atebimetinib (a MEK 1/2 inhibitor) plus modified gemcitabine and nab-paclitaxel will improve overall survival compared with standard gemcitabine and nab-paclitaxel. Further information: https://clinicaltrials.gov/study/NCT07562152	Peninsula University Hospital	OncologyResearch@phcn.vic.gov.au

**SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA**

Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
<u>BGB 58067</u> A Phase 1a/b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-58067, an MTA-Cooperative PRMT5 Inhibitor in Patients With Advanced Solid Tumors	MTAP loss	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: MTAP loss (pre-screening available) Exclusion: Prior treatment with PRMT5 or MAT2A inhibitor	<u>BGB-58067</u> BGB-58067 is an MTA-Cooperative PRMT5 inhibitor. Further information: NCT06589596 - Victorian Cancer Trials Link	Monash Health (Note: Austin Health is only recruiting GBM)	referrals.earlyphase@monashhealth.org *RESTRICTED RECRUITMENT*
<u>IKS014-01 (IKSUDA)</u> A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants With Advanced HER2+ Solid Tumors	HER2	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: HER2 IHC 1-3+ HER2 ISH negative and positive	<u>IKS014</u> IKS014 is a HER2 targeting antibody drug conjugate. Further information: https://trials.cancervic.org.au/details/vctlnct05872295	Peninsula and Southeast Oncology	ag@paso.com.au * NO SLOTS CURRENTLY AVAILABLE*
<u>BAY3498264</u> Phase 1 Study of a SOS1 Inhibitor, BAY 3498264, in Combination in Participants With Advanced KRASG12C-mutated Solid Tumors	SOS1 KRAS	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: KRAS G12C mutation	<u>BAY3498264</u> BAY3498264 is a SOS1 inhibitor. Treatment will be in combination with sotorasib. Further information: https://trials.cancervic.org.au/details/vctlnct06659341	Peninsula and Southeast Oncology	ag@paso.com.au



SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA

Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
<u>AK138D1</u> A First-in-human, Phase I Study of Evaluating Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AK138D1 in the Treatment of Advanced Solid Tumors	HER3	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: Exhausted conventional treatment	<u>Patritumab Deruxtecan</u> Patritumab Deruxtecan an anti-HER3 Antibody drug conjugate Further information: https://trials.cancervic.org.au/details/vctl_nct06730386	Peninsula and Southeast Oncology	ag@paso.com.au
<u>DT-7012-CLI-001</u> Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors (DOMISOL)	CCR8	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: Second or later line	<u>DT-7012</u> DT-7012 is an anti-CCR8 antibody. Further information: https://clinicaltrials.gov/study/NCT06819735	Peninsula and Southeast Oncology	ag@paso.com.au
<u>SNV4818</u> A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV4818 as Monotherapy or in Combination With Other Anticancer Agents in Participants With Advanced Solid Tumors	PIK3CA	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: Activating PIK3CA mutation Exhausted conventional treatment <i>Note: Pantumour for dose escalation cohorts</i>	<u>SNV4818</u> SNV4818 is an oral PI3K α inhibitor. SNV4818 will be delivered with or without fulvestrant Further information: NCT06736704 - Victorian Cancer	Monash Health	referrals.earlyphase@monashhealth.org * RESTRICTED RECRUITMENT* *PIK3Ca mutated solid tumours only*
<u>BNT317</u> A Phase I, First-in-human, Open-label, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BNT317 in Patients with Advanced Solid Tumors	CD39	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: Exhausted conventional treatment	<u>BT317</u> BT317 is administered intravenously Further information: NCT06750185 - Victorian Cancer Trials Link	Monash Health	referrals.earlyphase@monashhealth.org *RECRUITMENT ON HOLD* * NO SLOTS CURRENTLY AVAILABLE*



SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA

Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
<u>BNT327-09</u> A Clinical Trial Testing the Safety and efficacy of BNT327 when combined with chemotherapy for people who have not yet been treated for Pancreatic Cancer	N/A	METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) Inclusion: Treatment naïve	BNT327 (Pumitamig) Participants will receive BNT327 in combination with standard chemotherapy. BNT327 is a bi-specific antibody that works by simultaneously blocking PD-Li and neutralizing VEGF-A. Further information: https://clinicaltrials.gov/study/NCT07255404	Peninsula and South Eastern Haematology and Oncology Group St Vincent's Hospital	ag@paso.com.au OncologyTrialCoordinators@svha.org.au
<u>BNT3212</u> A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination with BNT327 in Adults with Advanced Solid Tumours	N/A	ADVANCED OR METASTATIC SOLID CANCERS	BNT3212 is a bispecific antibody-drug conjugate that targets EGFR and HER3 receptors commonly overexpressed in solid tumours. BNT327 is a bi-specific antibody that works by simultaneously blocking PD-L1 and neutralizing VEGF-A. Further information: https://trials.cancervic.org.au/details/vctl_nct07147348	Monash Health	referrals.earlyphase@monashhealth.org *RESTRICTED RECRUITMENT* *WAITLIST IN PLACE*
<u>LM350-01-10</u> A Phase I/II, First-in-Human (FIH), Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-350 in Patients with Advanced Solid Tumors	CDH17	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: Exhausted conventional treatment	LM350 is a CDH17 targeted antibody drug conjugate Further information: https://clinicaltrials.gov/study/NCT07112222	Peninsula and South Eastern Haematology and Oncology Group	ag@paso.com.au



SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA

Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
<u>TLN-372 (Treeline T1)</u> An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-372 as a Single Agent and in Combination With Other Anti-Tumor Agents, in Patients With Advanced KRAS Mutant Solid Tumors	KRAS	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: Second line onwards	<u>TLN-372</u> TLN-372 is a pan-KRAS inhibitor that will be administered as monotherapy or in combinations with cetuximab and pembrolizumab. Further information: https://trials.cancervic.org.au/details/vctlnct07204340	Peter MacCallum Cancer Centre	PCCTU.EDD@petermac.org
<u>TLN-372 (Treeline T2)</u> An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-372 as a Single Agent and in Combination With Other Anti-Tumor Agents, in Patients With Advanced KRAS Mutant Solid Tumors	KRAS	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: Second line onwards	<u>TLN-372</u> TLN-372 is a pan-KRAS inhibitor that will be administered in combination with cobicistat. Further information: https://anzctr.org.au/Trial/Registration	Peter MacCallum Cancer Centre	PCCTU.EDD@petermac.org
<u>IDOV-Immune for Advanced Solid Tumors</u> A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and	N/A	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: Exhausted conventional treatment	<u>IDOV-Immune</u> IDOV-immune is an oncolytic virus therapy administered intravenously. Further information: https://trials.cancervic.org.au/IDOVimmunotherapy	Alfred Health	act-m@alfred.org.au * LIMITED SLOTS AVAILABLE*



SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors.					
<u>IMD3030-01</u> A Multicenter Global Open-Label Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of IMD303 Injectable in Participants with Advanced Malignant Solid Tumors followed by Phase Ib/II Trial of Safety and Efficacy in Combination with PD-1 Inhibitor.	CTLA-4	ADVANCED OR RECURRENT MALIGNANT SOLID TUMOURS (including PDAC but note PDAC is not primary focus)	Treatment is IV IMD303, initially as monotherapy (Phase 1a; dose escalation/optimisation) then as combined therapy)Phase 1b/2a in combination with standard PD-1 inhibitor. Further information: https://anzctr.org.au/Trial/Registration/ACTRN12626000450314	Bendigo	MGarwood@bendigohealth.org.au
<u>BG-C0979</u> A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-C0979 in Patients With Selected Advanced Solid Tumors.	ADAM9	ADVANCED, METASTATIC OR UNRESECTABLE SOLID TUMOURS (focus is NSCLC and GI cancers)	Patients must have already received SOC systemic therapies. Treatment is IV BG-C0979 monotherapy or BC-C0979 combined with Tevimbra (Tislelizumab, a anti-PD-1 immunotherapy). Further information: https://clinicaltrials.gov/study/NCT07414836	Cabrini	clinicaltrials@cabrini.com.au *Restricted recruitment*

**SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA**

Trial Title	Targets (Genomic)	Target population <i>(Trial suitable for patients with this stage of pancreatic cancer)</i>	Treatment + Further Information <i>(What the study involves)</i>	Site <i>(Where the study is being offered)</i>	Contact Details <i>(Email the contact person listed with any enquiries)</i>
<u>BG-85738</u> A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-85738, Alone or in Combination With Other Antitumor Agents, in Patients With Advanced or Metastatic Solid Tumors With RAS Mutations.	KRAS & RAS variants	ADVANCED OR METASTATIC SOLID TUMOURS <i>(Second line +)</i>	Treatment is oral BG-85738 (initial study is dose escalation/optimisation). Further information: https://clinicaltrials.gov/study/NC07746141	Cabrini	clinicaltrials@cabrini.com.au *Restricted recruitment*
<u>VS-7375</u> A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients With Advanced KRAS G12D-Mutated Solid Tumors.	KRAS G12D	LOCALLY ADVANCED UNRESECTABLE OR METASTATIC SOLID TUMOURS <i>(Second line +)</i> Inclusion: 1 or 2 prior lines of SOC systemic therapy.	Treatment is oral VS-7375 monotherapy or combination therapy (VS-7375 with standard anti-EGFR therapies e.g. cetuximab) or VS-7375 alongside SOC chemo (Initial studies are dose escalation/optimisation). Further information: https://clinicaltrials.gov/study/NC07020221	Peninsula and South Eastern Haematology and Oncology Group	ag@paso.com.au
<u>HLX48</u> A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX48 (EGFR/c-MET Bispecific Antibody-Drug Conjugate) in Participants With Advanced/Metastatic Solid	EGFR & c-MET	LOCALLY ADVANCED UNRESECTABLE OR METASTATIC SOLID TUMOURS Inclusion: progressive or refractory disease following SOC or where there is not SOC available.	Treatment is IV HLX48 (first phase is dose escalation/optimisation) Further information: https://clinicaltrials.gov/study/NC07473726	Peninsula and South Eastern Haematology and Oncology Group	ag@paso.com.au



SOLID CANCER TRIALS ACCEPTING PANCREATIC CANCER IN VICTORIA					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
Tumors.					
<u>GFH276</u> A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors	KRAS & RAS variants	ADVANCED, LOCALLY ADVANCED OR METASTATIC SOLID TUMOURS (Second line +) Inclusion: following 1L therapy (or if no SOC therapy available).	Treatment is oral GFH276 (first phase is dose escalation) Further information: https://clinicaltrials.gov/study/NC07198321	Peninsula and South Eastern Haematology and Oncology Group	ag@paso.com.au



SUPPORTIVE CARE TRIALS FOR PATIENTS WITH PANCREATIC CANCER					
Trial Title	Targets (Genomic)	Target population <i>(Trial suitable for patients with this stage of pancreatic cancer)</i>	Treatment + Further Information <i>(What the study involves)</i>	Site <i>(Where the study is being offered)</i>	Contact Details <i>(Email the contact person listed with any enquiries)</i>
<u>DINE-PC</u> Dietetics Intervention and Nutritional Evaluation in Pancreatic Cancer Care (DINE-PC)	N/A	ALL STAGES OF PANCREATIC CANCER	Dietetics counselling Further information: https://www.pancreaticcentre.org.au/treatment/clinical-trials-and-research/dine-pc	Epworth Victoria	EH- PancreaticCentre@epworth.org.au
<u>SuperQol:</u> Assessing the impact of an intensive dietitian-led telehealth intervention focusing on nutritional adequacy and symptom control, on quality of life in patients with pancreatic cancer: a randomised controlled trial	N/A	ALL STAGES OF PANCREATIC CANCER	<u>Dietician counselling/intervention</u> Patients will be randomised to receive usual care or intensive dietetics intervention Further intervention: https://trials.cancervic.org.au/ /details/vct1_actrn126240000 84583	Latrobe Regional Hospital Victoria	clinicaltrials@lrh.com.au



<u>PANConnect</u> Assessing the effectiveness of a specialist cancer nurse-led telehealth model of care on pain and symptom management among Australians affected by pancreatic cancer: The PANConnect randomised controlled trial	N/A	ALL STAGES OF PANCREATIC CANCER	<u>PANConnect intervention</u> Participants allocated to the <u>PANConnect intervention</u> will continue to receive oncology care from their treating team. PANConnect comprises: Weekly patient symptom-reporting plus symptom assessment and subsequent care coordination by a specialist cancer nurse Further information: https://trials.cancervic.org.au/details/vct/actrn12624001034527	Austin Health Bendigo Health Border Medical Oncology Monash Health Peninsula Health Peter MacCallum Cancer Centre St Vincent's Hospital Melbourne Warringal Private Hospital	PANConnect-Study@petermac.org
--	-----	--	--	--	--

**Phase 1 Trials are offered in Victoria at the following locations:**

Study Site	Contact	Email	Phone
Alfred Hospital (Pahran VIC 3004)	Clinical Trial Team	moncACT1@alfredhealthconnect.onmicrosoft.com	TBA
Austin Hospital (Heidelberg VIC 3084)	Samantha Chakar	samantha.chakar@austin.org.au	03 9496 3088
Barwon Health (Geelong VIC 3220)	Karen Aitken	cstu.manager@barwonhealth.org.au	03 4215 2758
Cabrini Malvern (Malvern VIC 3144)	Rochelle Woods	rwoods@cabrini.com.au	95083437
Epworth Hospital (Richmond VIC 3121)	Clinical Research Coordinator	ehjreissaticentre@epworth.org.au	0448 842 680 or 03 9426 8880
PASO Medical (Frankston VIC 3199)	Albert Goikman Clinical Trials Manager	ag@paso.com.au	03 91131307
Monash Health (Clayton VIC 3168)	Early Phase Research Study Coordinator	referrals.earlyphase@monashhealth.org	0474 769 510
Peter MacCallum Cancer Centre (Parkville VIC 3052)	Enquiries Line Coordinator	clinicaltrials.enquiries@petermac.org	03 8559 7456 (9am-2pm, Mon-Fri)
St Vincent's Hospital (Fitzroy VIC 3065)	Nadia Ranieri	oncology.research@svha.org.au	03 9231 3167
Western Health (St Albans VIC 3021)	Heike Raunow	CancerClinicalTrials@wh.org.au	03 83959136 or 0434915739

For patients not eligible for any of the above trials, and who have pancreatic cancer that has progressed, are intolerant or are ineligible for standard of care treatments, please consider a phase 1 trial. Clinicians can email or phone the contact listed with any enquiries. Patients, please contact your treating Medical Oncologist if you wish to discuss phase 1 trials.



PANCREATIC OR SOLID CANCER TRIALS OUTSIDE OF VICTORIA

Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
<u>KONQUER-101</u> A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.	RAS	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: RAS mutant PDAC, CRC, NSCLC, or other solid tumour	BBO-11818 is a pan-RAS inhibitor and will be administered alone or in combinations with chemotherapy and/or pembrolizumab Further information: https://clinicaltrials.gov/study/NCT06917079	GenesisCare St Leonards North Shore Health Hub (NSW)	admin.northshore@genesiscare.com * NO PDAC SLOTS CURRENTLY AVAILABLE*
<u>ALKOVE-1</u> A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-to655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-to1)	ALK	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: ALK rearrangement or activating ALK mutation	NVL655(neladalkib) is an oral selective ALK inhibitor. Further information: https://www.cancer.nsw.gov.au/research-and-data/cancer-clinical-trials-in-nsw/find-a-cancer-clinical-trial-in-nsw/item?r=13595	Royal North Shore Hospital NSW	PI: malinda.itchins@sydney.edu.au Trial coordinator: shirley.liang@health.nsw.gov.au
<u>BGB-58067</u> A Phase 1a/b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-58067, an MTA-Cooperative PRMT5 Inhibitor in Patients With Advanced Solid Tumors	MTAP deficiency	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: Any treatment line	BGB-58067 is a PMRT5 inhibitor Further information: https://www.cancer.nsw.gov.au/research-and-data/cancer-clinical-trials-in-nsw/find-a-cancer-clinical-trial-in-nsw/item?r=14130	Blacktown Cancer & Haematology Centre (NSW) Westmead Hospital (NSW)	raymond.tanganan@health.nsw.gov.au Adnan.Nagrial@health.nsw.gov.au



PANCREATIC OR SOLID CANCER TRIALS OUTSIDE OF VICTORIA					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
<u>GeneScreen 5FU</u> DPYD Genotype-guided dose Personalisation for Fluoropyrimidine prescribing in Cancer	DPYD	SOLID CANCERS – ALL STAGES Inclusion: Intention to treat with Fluoropyrimidine (FP) containing chemotherapy Exclusion: Prior FP containing chemotherapy prior to study entry	DPYD genotyping Pre-emptive DPYD genotyping prior to commencing Fluoropyrimidine chemotherapy Further information: ANZCTR - Registration	Lake Macquarie Private Hospital (NSW)	ClinicalTrialsUnit.LMP@ramsayhealth.com.au
				Fiona Stanley Hospital (WA)	audrey.margery-Muir@health.wa.gov.au
<u>BAY3713372</u> A first in human study to evaluate the safety, tolerability, and pharmacokinetics, pharmacodynamics, and preliminary clinical activity of BAY 3713372, a novel 2 nd generation PRMT5 inhibitor in participants with MTAP deleted solid tumors	MTAP loss	ADVANCED OR METASTATIC SOLID CANCERS Inclusion Systemic Treatment naive or treatment exposed advanced pancreatic adenocarcinoma Homozygous MTAP deletion	BAY 3713372 is a novel 2 nd generation PRMT5 inhibitor. Further information: https://www.cancer.nsw.gov.au/research-and-data/cancer-clinical-trials-in-nsw/find-a-cancer-clinical-trial-in-nsw/item?r=14234	Chris O'Brien Lifehouse	teresa.nicholls@lh.org.au
<u>AMG 410</u> A Phase 1/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors	KRAS	ADVANCED OR METASTATIC SOLID CANCERS <i>(Exhausted standard of care)</i> Inclusion: KRAS mutation or amplification Exhausted conventional treatment options Pancreatic cohort specified in part 2.	AMG 410 is an oral pan-KRAS inhibitor and will be administered alone or in combination with pembrolizumab and panitumumab Further information: https://www.cancer.nsw.gov.au/find-a-cancer-clinical-trial-in-nsw/item?r=14288	Chris O'Brien Lifehouse	jasmine.sell@lh.org.au * LIMITED SLOTS AVAILABLE* *Long waitlist for PDAC*



PANCREATIC OR SOLID CANCER TRIALS OUTSIDE OF VICTORIA					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
INVOKE (OKN-4395-121) A Phase 1, Open-label, Multicenter, Dose-escalation and Cohort Expansion Study of OKN4395, a Triple Antagonist of EP2, EP4, and DP1 Prostanoid Receptors, as Monotherapy and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors	EP2, EP4, DP1	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: Phase 1a – Exhausted SOC Phase 1b – no more than 3 prior lines of therapy	OKN4395 is a triple agonist of EP2, EP4, and DP1 prostanoid receptors. This will be administered alone or in combination with pembrolizumab Further information: https://www.cancer.nsw.gov.au/research-and-data/cancer-clinical-trials-in-nsw/find-a-cancer-clinical-trial-in-nsw/item?r=14182	Chris O'Brien Lifehouse	teresa.nicholls@lh.org.au
HD-PRiMe Feasibility of delivering High Dose Palliative Radiotherapy in patients with Metastatic malignancy	N/A	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: Unsuitable for systemic treatment	Radiotherapy High dose palliative radiotherapy Further information: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=390482	Sunshine Coast University Hospital (QLD)	SC-Oncologytrials@health.qld.gov.au
AK138D1 A First-in-human, Phase I Study of Evaluating Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AK138D1 in the Treatment of Advanced Solid Tumors.	HER3	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: Exhausted conventional treatment	Patritumab Deruxtecan is an anti-HER3 Antibody drug conjugate. Further information: https://www.cancer.nsw.gov.au/cancer-clinical-trial-in-nsw/14186	Blacktown Cancer & Haematology Centre (NSW) Westmead Hospital (NSW)	raymond.tanganan@health.nsw.gov.au Adnan.Nagrial@health.nsw.gov.au



PANCREATIC OR SOLID CANCER TRIALS OUTSIDE OF VICTORIA					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
<u>River (C3651021)</u> A Study to Learn About the Medicine Pongegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue.	GDF-15	METASTATIC/LOCALLY ADVANCED (First line) Inclusion: Metastatic pancreatic ductal adenocarcinoma Can have received first cycle of chemotherapy but prior to second cycle Cachexia defined by Fearon criteria of weight loss	Pongegromab is a monoclonal antibody aiming to treat cancer cachexia for targeting GDF-15 Patients are treated with first line chemotherapy (gemcitabine + nab-paclitaxel or mFOLFIRINOX) and randomized to receive pongegromab or placebo Further information: https://clinicaltrials.gov/study/NCT06989437	Westmead Hospital (NSW)	Adnan.Nagrial@health.nsw.gov.au
<u>BGB 53038</u> A Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-53038, a Pan-KRAS Inhibitor, As Monotherapy or in Combinations in Patients with Advanced or Metastatic Solid Tumors with KRAS Mutations or Amplifications	KRAS mutation or wildtype amplification	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: Evidence of KRAS mutation or wild-type amplification Exclusion: KRAS G12R mutation Prior treatment with other RAS targeting treatment	BGB-53038 is a pan-KRAS inhibitor. Further information: https://www.cancer.nsw.gov.au/research-and-data/cancer-clinical-trials-in-nsw/fin193d-a-cancer-clinical-trial-in-nsw/item?r=14188	Westmead Hospital (NSW)	Adnan.Nagrial@health.nsw.gov.au



PANCREATIC OR SOLID CANCER TRIALS OUTSIDE OF VICTORIA					
Trial Title	Targets (Genomic)	Target population <i>(Trial suitable for patients with this stage of pancreatic cancer)</i>	Treatment + Further Information <i>(What the study involves)</i>	Site <i>(Where the study is being offered)</i>	Contact Details <i>(Email the contact person listed with any enquiries)</i>
<u>RASolute 303 / RMC6236-303</u> RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel Versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma.	KRAS & RAS variants	METASTATIC <i>(First line)</i> Inclusion: Previously untreated for the metastatic disease.	Patients are randomised 1:1:1 to either SOC (gem/abraxane), oral Daraxonrasib alone or oral Daraxonrasib combine with SOC gem/abraxane Further information: https://clinicaltrials.gov/study/NC07491445	PWH	Felicity.Kenney@health.nsw.gov.au
<u>BNT327-09</u> A Phase II, Multi-site, Randomized, Open-label, Trial of Pumitamig in Combination With Chemotherapy in Patients With Metastatic Pancreatic Cancer.	PD-L1 & VEGF-A	METASTATIC Inclusion: PDAC who have not undergone first line therapy.	Treatment is IV BNT327 (Pumitamig) paired with SOC chemotherapy (mFOLFIRINOX or gem/abraxane) Further information: https://clinicaltrials.gov/study/NC07255404	Westmead Hospital (NSW)	Adnan.Nagrial@health.nsw.gov.au

**PANCREATIC OR SOLID CANCER TRIALS OUTSIDE OF VICTORIA**

Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
<u>DB-1311</u> A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects With Advanced/Metastatic Solid Tumors.	B7-H3	ADVANCED OR METASTATIC SOLID CANCERS (including PDAC)	This study (NCT05914116) is for the initial Phase 1/2a trial for dose escalation/optimisation. Phase 2/3 will be open later (randomised). Further information: https://clinicaltrials.gov/study/NCT05914116	Westmead Hospital (NSW)	Adnan.Nagrial@health.nsw.gov.au

PANCREATIC CANCER TRIALS IN SINGAPORE

Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
<u>Bayer 22931</u> A first in human study to evaluate the safety, tolerability, and pharmacokinetics, pharmacodynamics, and preliminary clinical activity of BAY 3713372, a novel 2 nd generation PRMT5 inhibitor in participants with MTAP deleted solid tumors	MTAP loss	ADVANCED OR METASTATIC SOLID CANCERS Inclusion Systemic Treatment naive or treatment exposed advanced pancreatic adenocarcinoma Homozygous MTAP deletion	<u>BAY 3713372</u> BAY 3713372 is a novel 2 nd generation PRMT5 inhibitor. Further information: https://clinicaltrials.gov/study/NCT06914128	National Cancer Centre Singapore National University Hospital Singapore	Wang.jue.lynn@nccs.com.sg global-roche-genentech-trials@gene.com * RESTRICTED RECRUITMENT* Waitlist Only



PANCREATIC CANCER TRIALS IN SINGAPORE					
Trial Title	Targets (Genomic)	Target population (Trial suitable for patients with this stage of pancreatic cancer)	Treatment + Further Information (What the study involves)	Site (Where the study is being offered)	Contact Details (Email the contact person listed with any enquiries)
<u>GO45416 (GDC-7035)</u> A phase I/II Dose-Escalation and expansion study evaluating the safety, pharmacokinetics, and activity of GDC-7035 as a single agent and in combination with other anti-cancer therapies in patients with advanced solid tumors with a KRAS G12D mutation	KRAS G12D	METASTATIC/LOCALLY ADVANCED Inclusion: Systemic Treatment refractory KRAS G12D pancreatic adenocarcinoma	<u>GDC-7035</u> GDC-7035 is a KRAS G12D inhibitor Further information: https://clinicaltrials.gov/study/NC06619587	National Cancer Centre Singapore	Ye.xin@nccs.com.sg
<u>EBC 129-01</u> EBC 129-01 - A Phase 1A/B Study to Evaluate the Safety and Tolerability of EBC 129 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumours	anti N256- glycosylate d CEACAM5 and CEACAM6	ADVANCED OR METASTATIC SOLID CANCERS Inclusion: Exhausted standard of care treatment options	<u>EBC129</u> EBC129 is an anti-N256- glycosylated CEACAM5 and CEACAM6 antibody drug conjugate. EBC129 will be administered alone or in combination with pembrolizumab Further information: https://clinicaltrials.gov/study/NCT05701527	National University Hospital Singapore	Venkateshan_Srirangam@eddc.sg * RESTRICTED RECRUITMENT *



PANCREATIC CANCER PREVENTION					
Trial Title	Targets (Genomic)	Target population <i>(Trial suitable for patients with this stage of pancreatic cancer)</i>	Treatment + Further Information <i>(What the study involves)</i>	Site <i>(Where the study is being offered)</i>	Contact Details <i>(Email the contact person listed with any enquiries)</i>
<u>APRISE</u> Assess the effectiveness of the Australian Pancreatic High-Risk Screening Program in identifying early-stage pancreatic cancer among high-risk individuals due to familial or genetic risk factors	NA	FAMILY HISTORY OF PANCREATIC CANCER Inclusion: High risk features for pancreatic cancer development	<u>Screening</u> Screening with endoscopic ultrasound or MRI for a period of 10 years Further information: https://trials.cancervic.org.au/details/vct1_actrn12624000421538	Epworth Health	EJReissatiCentre@epworth.org.au